GCP
BBIO icon

GSA Capital Partners’s BridgeBio Pharma BBIO Stock Holding History

GSA Capital Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Buy
+2,829
New +$205K 0.01% 1433
2025
Q4 		– Sell
-7,299
Closed -$379K – 1676
2025
Q3 		$379K Sell
7,299
-1,841
-20% -$89.8K 0.03% 1048
2025
Q2 		$395K Sell
9,140
-1,389
-13% -$50.5K 0.03% 1086
2025
Q1 		$364K Buy
+10,529
New +$355K 0.03% 1018
2024
Q3 		– Sell
-21,421
Closed -$543K – 1598
2024
Q2 		$543K Buy
+21,421
New +$586K 0.04% 910
2023
Q4 		– Sell
-86,071
Closed -$2.27M – 1505
2023
Q3 		$2.27M Buy
+86,071
New +$2.44M 0.19% 74
2023
Q2 		– Sell
-27,908
Closed -$463K – 1517
2023
Q1 		$463K Sell
27,908
-9,593
-26% -$112K 0.05% 766
2022
Q4 		$286K Sell
37,501
-6,190
-14% -$59.3K 0.04% 954
2022
Q3 		$434K Sell
43,691
-61,486
-58% -$639K 0.06% 682
2022
Q2 		$955K Buy
105,177
+70,164
+200% +$587K 0.14% 165
2022
Q1 		$355K Buy
35,013
+21,124
+152% +$217K 0.05% 774
2021
Q4 		$232K Sell
13,889
-82,107
-86% -$3.47M 0.03% 1118
2021
Q3 		$4.5M Buy
95,996
+84,749
+754% +$4.54M 0.46% 8
2021
Q2 		$686K Buy
+11,247
New +$642K 0.08% 430
2021
Q1 		– Sell
-10,385
Closed -$738K – 1101
2020
Q4 		$738K Sell
10,385
-69,505
-87% -$3.35M 0.12% 226
2020
Q3 		$3M Buy
+79,890
New +$2.51M 0.5% 9

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's BBIO Position: Q1 2026 in Review

GSA Capital Partners opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 2,829 shares worth $210K. The stake represents 0.01% of the portfolio and ranks #1433 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in BBIO as recently as Q3 2025.

GSA Capital Partners first reported a position in BBIO in Q3 2020 and has held it in 16 quarters since. The position peaked at $4.5M in Q3 2021. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • GSA Capital Partners held 2,829 shares of BridgeBio Pharma worth $210K as of Q1 2026.
  • BridgeBio Pharma was a new GSA Capital Partners position in Q1 2026.
  • BridgeBio Pharma made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1433 holding.
  • GSA Capital Partners first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 16 quarters since.
  • GSA Capital Partners's BridgeBio Pharma position peaked at $4.5M in Q3 2021.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.